香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年10月13日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-162 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年10月13日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 13, with Northeast Electric (00042) leading with a premium rate of 757.14% [1][2]. AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) with a premium rate of 757.14% and a deviation value of -56.53% [2][3] - Hongye Futures (03678) with a premium rate of 233.76% and a deviation value of 4.65% [2] - Andeli Juice (02218) with a premium rate of 230.75% and a deviation value of 2.26% [2] - The bottom three stocks with the lowest AH premium rates are: - Ningde Times (03750) with a premium rate of -18.07% and a deviation value of -4.75% [2] - Heng Rui Medicine (01276) with a premium rate of -3.16% and a deviation value of -0.87% [2] - China Merchants Bank (03968) with a premium rate of 4.43% and a deviation value of -1.34% [2] Deviation Value Rankings - The top three stocks with the highest deviation values are: - Sanhua Intelligent Control (02050) with a deviation value of 20.82% [3] - COSCO Shipping Development (02866) with a deviation value of 17.57% [3] - Kanglong Chemical (03759) with a deviation value of 15.35% [3] - The bottom three stocks with the lowest deviation values are: - Northeast Electric (00042) with a deviation value of -56.53% [3] - Shanghai Electric (02727) with a deviation value of -21.93% [3] - Qin Port Co. (03369) with a deviation value of -11.51% [3]

Core Viewpoint - Heng Rui Medicine (01276.HK) announced a share buyback of 170,000 A-shares at a total cost of RMB 11.35 million, with a buyback price range of RMB 66.18 to 67.01 per share [1] Related Events - Heng Rui Medicine (01276.HK) conducted a buyback on October 13, spending RMB 11.35 million to repurchase 170,000 A-shares [1] - The company plans to hold a board meeting on October 27 to approve its quarterly performance [1]

Core Viewpoint - Heng Rui Medicine (01276) announced a share buyback of 170,000 A-shares at a cost of 11.35 million yuan on October 13, 2025 [1] Summary by Category - **Company Actions** - The company plans to repurchase shares, indicating confidence in its stock value and future prospects [1] - **Financial Details** - The total expenditure for the buyback is 11.35 million yuan, which translates to approximately 1.135 million dollars [1]

表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 呈交日期： 2025年10月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | ...

格隆汇10月13日丨恒瑞医药(01276.HK)宣布，董事会会议将于2025年10月27日(星期一)举行，藉以(其中 包括)考虑及批准本公司及其附属公司截至2025年9月30日止九个月的季度业绩及其发布。 ...

（股份代號：1276） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 江蘇恒瑞醫藥股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會 議將於2025年10月27日（星期一）舉行，藉以（其中包括）考慮及批准本公司及其 附屬公司截至2025年9月30日止九個月的季度業績及其發佈。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年10月13日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 ...

Summary of Hengrui Pharmaceuticals Conference Call Company Overview - **Company**: Hengrui Pharmaceuticals - **Industry**: Pharmaceuticals - **Market Cap**: RMB 474.9 billion - **Ticker**: 600276 CH - **Current Price**: RMB 71.55 - **Price Target**: RMB 86.00 (+20% upside) [7][10] Key Takeaways 1. Global Strategy and Partnerships - Hengrui's ex-China strategy aims to maximize asset value through out-licensing and equity-linked NewCo structures, exemplified by the collaboration with GSK, which includes multi-asset components and a 30% equity stake in NewCo [2][19] - The company is leveraging partnerships with multinational corporations (MNCs) like GSK and Merck to enhance its global reach while maintaining control over development and commercialization [2][21] 2. Pipeline Development - Hengrui is focusing on core therapeutic areas: oncology, metabolic/cardiovascular, immunology/respiratory, and neurology, with significant emphasis on metabolic innovation [3][25] - Key programs include dual and triple agonists, oral GLP-1 small molecules, and injectable peptides aimed at treating obesity and diabetes [3][22] 3. Financial Performance and Business Development - In 2025, Hengrui executed high-value business development deals, generating RMB 2 billion in income in the first half, leading to a margin expansion to 86.6% [4][10] - The company targets a 25% CAGR for innovative drugs over three years, showcasing disciplined capital allocation and strategic optionality [4][10] 4. Market Dynamics in China - China's evolving market, supported by government incentives and emerging commercial insurance models, is expected to drive growth and expand access to innovative therapies [5][27] - Hengrui anticipates sustained margin expansion as its portfolio transitions from generics to innovative products, particularly in obesity and cardiovascular markets [5][30] 5. Competitive Positioning - Hengrui is positioned to compete effectively in the Lp(a) and cardiovascular markets, with a small molecule program that is less than a year behind competitors like Lilly [23][30] - The company is exploring both primary and secondary prevention strategies in cardiovascular health, which could provide earlier market entry opportunities [23][30] 6. Regulatory Advantages - Hengrui plans to leverage China's regulatory advantages to accelerate clinical trial timelines, ensuring consistency across multi-regional trials [24][30] - The company is focused on meeting global regulatory standards while addressing ethnic diversity requirements [24][30] 7. Long-Term Growth and Margins - Hengrui expects profit margins to improve as its pipeline shifts towards innovative drugs, which typically carry higher margins [30][10] - The company is diversifying across therapeutic areas to address significant unmet medical needs both domestically and globally [26][30] 8. Risks and Challenges - Potential risks include GPO/NRDL negotiation challenges, R&D risks, and intensified market competition [33][10] - The company is also navigating the complexities of commercial insurance in China, which currently has limited penetration but is expected to grow over the next decade [27][30] Conclusion Hengrui Pharmaceuticals is strategically positioned for growth through innovative drug development, global partnerships, and leveraging regulatory advantages in China. The company's focus on high-value business development and a diversified pipeline across key therapeutic areas supports its long-term profitability and competitive resilience in the biopharma landscape.

Core Insights - The top three companies with the highest short positions as of October 3 are COSCO Shipping Holdings (01919), Ganfeng Lithium (01772), and ZTE Corporation (00763), with short ratios of 15.66%, 15.25%, and 15.16% respectively [1][2] - Ganfeng Lithium (01772) saw the largest absolute increase in short positions, rising by 1.20%, followed by Minmetals Resources (01208) with an increase of 0.96%, and Yuexiu Transport Infrastructure (01052) with an increase of 0.76% [1][2] - The companies with the largest decreases in short positions include GCL-Poly Energy (03800), which decreased by 3.16%, followed by Dongfang Electric (01072) with a decrease of 2.03%, and Jinxin Fertility (01951) with a decrease of 0.76% [1][3] Summary of Short Positions - **Top 10 Companies by Short Ratio** - COSCO Shipping Holdings (01919): 15.66% (from 437 million shares to 451 million shares) - Ganfeng Lithium (01772): 15.25% (from 62.30 million shares to 67.64 million shares) - ZTE Corporation (00763): 15.16% (from 113 million shares to 115 million shares) - CATL (03750): 13.83% (from 21.12 million shares to 21.57 million shares) - Vanke (02202): 12.63% (from 268 million shares to 279 million shares) - Ping An Insurance (02318): 12.59% (from 959 million shares to 938 million shares) - Zijin Mining (02899): 12.58% (from 750 million shares to 754 million shares) - MicroPort Medical (00853): 11.10% (from 213 million shares to 212 million shares) - Hansoh Pharmaceutical (01276): 11.01% (from 28.01 million shares to 28.43 million shares) - Fuyao Glass (06865): 10.85% (from 49.22 million shares to 47.94 million shares) [2] - **Top 10 Companies with Increased Short Positions** - Ganfeng Lithium (01772): Increased by 1.20% (from 14.05% to 15.25%) - Minmetals Resources (01208): Increased by 0.96% (from 1.96% to 2.93%) - Yuexiu Transport Infrastructure (01052): Increased by 0.76% (from 1.08% to 1.84%) - Jinli Permanent Magnet (06680): Increased by 0.66% (from 7.76% to 8.42%) - China Civil Aviation Information Network (00696): Increased by 0.58% (from 6.63% to 7.21%) [2] - **Top 10 Companies with Decreased Short Positions** - GCL-Poly Energy (03800): Decreased by 3.16% (from 11.76% to 8.59%) - Dongfang Electric (01072): Decreased by 2.03% (from 6.78% to 4.75%) - Jinxin Fertility (01951): Decreased by 0.76% (from 10.61% to 9.85%) - Yangtze Optical Fibre and Cable (06869): Decreased by 0.75% (from 7.03% to 6.28%) - Shanghai Electric (02727): Decreased by 0.72% (from 2.25% to 1.52%) [3][4]